Could a pill protect babies from stomach bugs? new vaccine trial in moms
NCT ID NCT07254728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an oral norovirus vaccine in 76 healthy breastfeeding mothers to see if it is safe and can trigger immune responses in both mom and her breastmilk. The vaccine is taken as a tablet and targets two common norovirus strains. Researchers hope that antibodies passed through breastmilk could protect nursing infants from severe stomach infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral bivalent norovirus vaccine (GI.1 and GII.4 strains)
- What this could lead to
- If it works, this could help protect infants from norovirus through their mother's breastmilk, potentially reducing severe diarrhea in babies.
- What could go wrong
- This is a very early phase 1 trial with only 76 participants, so it's mainly checking safety. It may not show strong immune responses or lead to a licensed vaccine.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOROVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
FCRN Clinical Trials Centre (Pty) Ltd
Vereeniging, 1935, South Africa
-
Newtown Clinical Research Centre
Johannesburg, 2001, South Africa
-
Progress Clinical Research Unit
Honeydew, 2040, South Africa
-
Trident Clinical
Kimberley, 8301, South Africa
-
WITS RHI Research Centre
Hillbrow, 2001, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.